CStone Pharmaceuticals announced that its Hong Kong-listed shares will be added to the Southbound Stock Connect eligible securities list effective 7 September 2026. The inclusion is expected to expand the company’s mainland investor base and improve secondary-market liquidity.

Chief Executive Officer Dr. Jason Yang said the recognition underscores market confidence in CStone’s innovation capabilities and long-term growth prospects. Management intends to leverage the broader shareholder reach to support ongoing global development and commercialisation initiatives.

Pipeline highlights: • CS2009, a PD-1/VEGF/CTLA-4 trispecific antibody, is advancing through global Phase I/II trials, with the first Phase III registrational studies slated to commence by end-2026. • CS5007, an EGFR/HER3 bispecific ADC, is in global Phase I trials across China and Australia. • Additional next-generation ADCs and bispecific antibodies in immunology and inflammation are progressing toward Investigational New Drug submissions.

Operational snapshot: • Founded in 2015, CStone has launched four innovative drugs to date. • The company has secured 21 new drug application approvals spanning nine indications. • The current R&D pipeline comprises 13 innovative assets, including ADCs, multispecific antibodies, immunotherapies and precision medicines.

CStone reiterated its commitment to addressing unmet clinical needs through a differentiated innovation strategy and efficient pipeline execution while aiming to deliver sustainable long-term value for shareholders.

Investors are advised to exercise caution when dealing in the company’s securities, as the announcement contains forward-looking statements that may differ from future outcomes.